Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.

BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increa...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Tinsley, J, Fairclough, R, Storer, R, Wilkes, F, Potter, A, Squire, SE, Powell, D, Cozzoli, A, Capogrosso, R, Lambert, A, Wilson, F, Wren, S, De Luca, A, Davies, K
Natura:	Journal article
Lingua:	English
Pubblicazione:	Public Library of Science 2011

Documenti analoghi

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
di: Jonathon M Tinsley, et al.
Pubblicazione: (2011-05-01)

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
di: Tinsley, J, et al.
Pubblicazione: (2013)

Up-regulation of utrophin alleviates the dystrophic phenotype in the mdx mouse heart
di: Sang, E, et al.
Pubblicazione: (2000)

Non-toxic ubiquitous overexpression of utrophin in the mdx mouse.
di: Fisher, R, et al.
Pubblicazione: (2000)

Non-toxic ubiquitous over-expression of utrophin in the mdx mouse.
di: Fisher, R, et al.
Pubblicazione: (2001)

Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system.
di: Squire, S, et al.
Pubblicazione: (2002)

Chronic Dosing with Membrane Sealant Poloxamer 188 NF Improves Respiratory Dysfunction in Dystrophic Mdx and Mdx/Utrophin-/- Mice.
di: Bruce E Markham, et al.
Pubblicazione: (2015-01-01)

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy
di: Fairclough, R, et al.
Pubblicazione: (2008)

Utrophin in the therapy of Duchenne Muscular Dystrophy
di: Potter, A, et al.
Pubblicazione: (2006)

Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.
di: Wakefield, P, et al.
Pubblicazione: (2000)

Utrophin upregulation in DMD therapy: current status and new tools for the future
di: Fairclough, R, et al.
Pubblicazione: (2011)

Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
di: Kennedy, T, et al.
Pubblicazione: (2017)

Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
di: Tahnee L. Kennedy, et al.
Pubblicazione: (2017-10-01)

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy
di: Fairclough, R, et al.
Pubblicazione: (2012)

Muscle structure influences utrophin expression in mdx mice.
di: Glen B Banks, et al.
Pubblicazione: (2014-06-01)

A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration.
di: Weir, A, et al.
Pubblicazione: (2004)

Erythropoietin reduces the expression of myostatin in mdx dystrophic mice
di: D. Feder, et al.
Pubblicazione: (2014-11-01)

Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2/mdx mice
di: Kennedy, T, et al.
Pubblicazione: (2018)

Heregulin ameliorates the dystrophic phenotype in mdx mice.
di: Krag, T, et al.
Pubblicazione: (2004)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
di: Goyenvalle, A, et al.
Pubblicazione: (2010)

Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.
di: Chancellor, DR, et al.
Pubblicazione: (2011)

Utrophin luciferase knock-in mouse model for in vivo assessment of drug efficacy in preclinical trials for utrophin upregulation
di: Fairclough, R, et al.
Pubblicazione: (2010)

Characterisation of utrophin modulator SMT C1100 as a non-competitive inhibitor of firefly luciferase
di: Wilkinson, I, et al.
Pubblicazione: (2019)

T-cell-dependent fibrosis in the mdx dystrophic mouse.
di: Morrison, J, et al.
Pubblicazione: (2000)

Decrease in prosaposin in the Dystrophic mdx mouse brain.
di: Hui-Ling Gao, et al.
Pubblicazione: (2013-01-01)

Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
di: Cerletti, M, et al.
Pubblicazione: (2003)

A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle.
di: Weir, A, et al.
Pubblicazione: (2002)

Cardioprotective Effect of Whole Body Periodic Acceleration in Dystrophic Phenotype mdx Rodent
di: Arkady Uryash, et al.
Pubblicazione: (2021-05-01)

l-arginine improves dystrophic phenotype in mdx mice
di: Vincent Voisin, et al.
Pubblicazione: (2005-10-01)

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers
di: Tinsley, J, et al.
Pubblicazione: (2015)

Lipidomic Analyses Reveal Specific Alterations of Phosphatidylcholine in Dystrophic Mdx Muscle
di: William J. Valentine, et al.
Pubblicazione: (2022-01-01)

Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction.
di: Manoj K Mishra, et al.
Pubblicazione: (2017-01-01)

Second-generation compound for the modulation of utrophin in the therapy of DMD
di: Guiraud, S, et al.
Pubblicazione: (2015)

Increased susceptibility of the dystrophic mdx mouse heart to ischemic and hypoxic injuries
di: Zhang, W, et al.
Pubblicazione: (2005)

Metabolic remodeling of dystrophic skeletal muscle reveals biological roles for dystrophin and utrophin in adaptation and plasticity
di: Justin P. Hardee, et al.
Pubblicazione: (2021-03-01)

Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice.
di: Yusuke Echigoya, et al.
Pubblicazione: (2013-01-01)

Dystrophic phenotype improvement in the diaphragm muscle of mdx mice by diacerhein.
di: Rafael Dias Mâncio, et al.
Pubblicazione: (2017-01-01)

Proteome Profiling of the Dystrophic <i>mdx</i> Mice Diaphragm
di: Olga Mucha, et al.
Pubblicazione: (2023-11-01)

Choline administration attenuates aspects of the dystrophic pathology in mdx mice
di: Francesca M. Alves, et al.
Pubblicazione: (2019-04-01)

Dysfunctional muscle and liver glycogen metabolism in mdx dystrophic mice.
di: David I Stapleton, et al.
Pubblicazione: (2014-01-01)